(Ambrisentan) is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO class II or III symptoms. Letairis is intended to improve exercise capacity and delay clinical worsening.

Manufactured by: Gilead Sciences.Inc

Active Ingredient(s): Ambrisentan 

Dosage Form:  Tablet, oral

Strength:  5 mg, 10 mg

FDA approved: June 15, 2007

More information on Letairis:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf

www.gilead.com/~/media/files/pdfs/medicines/cardiovascular/letairis/letairis_pi.pdf